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Abstract
Molecular medicine describes molecular structures and mechanisms and this 
chapter focuses on molecular and genetics errors of diseases. Diseases can be 
classified into deficiency diseases, hereditary diseases, infectious diseases and 
physiological diseases and to get a glimpse of the mechanisms the chapter covers 
the most common disease of each class.
Keywords: chromosomal diseases, cancer, neurodegenerative diseases, pulmonary 
diseases, obesity-induced insulin resistance, lymphoblastic leukemia, viral 
immunology and infectious diseases
1. Introduction
Distinct diseases have different etiology pattern and this chapter covers the 
chromosomal diseases, cancer, neurodegenerative diseases, pulmonary diseases, 
obesity-induced insulin resistance, lymphoblastic leukemia, viral immunology 
and infectious diseases. These communicable and non-communicable diseases 
negatively affect structure-function of the organism and specific symptoms are 
associated with these conditions. Pathogens or internal dysfunctions may lead these 
diseases. The chapter provides pathology of selected diseases from each class along 
with the molecular mechanisms.
1.1 Chromosomal diseases
1.1.1 Down syndrome
Down syndrome (DS) is the most common chromosomal genetic disorder. The 
disease is caused by the trisomy of human chromosome 21 (HSA21) and is also the 
most genetic mental disability [1]. The HSA21 mosaic can also lead to DS. Maternity 
age is an important aspect in the formation of an individual with DS [2]. The main 
cause of this disease is the absence of normal chromosome separation during meiosis 
and the production of gametes with two copies of chromosome copies instead of 
a single copy. As a result, DS individuals have trisomy 21 in some body cells, and a 
normal number of chromosomes in others. This is called mosaicism and is seen in 
approximately 4% of DS individuals. The term mosaicism was first reported in 1961 
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[3] and can occur in two ways: either a normal zygote is exposed to an early mitotic 
error following fertilization, which results in trisomy 21 in some cells, or an early 
mitotic error in some cells allows it to return to normal karyotype [4].
HSA21 is the most studied human chromosome, and since the long arm of 
chromosome 21 has been fully sequenced, a significant progress has been made in 
understanding its functional genomic units. HSA21 is the smallest chromosome 
and the overall gene density per megabase is about 15 genes per Mb (for the human 
genome) [5]. HSA21 is also very rich in long encoding RNA (lncRNA) genes, and, 
one of the poorest for genes encoding microRNA (miRNA). Also, the gene density 
is average for pseudogenes encoding the protein per Mb [6]. HSA21 is a weak 
chromosome in non-encoding RNAs (ncRNAs) and long nuclear elements (LINE). 
Interestingly, HSA21 shows significant enrichment for proteins found in cytoskel-
eton structures. These cytoskeletal proteins are known to play a role in neurological 
disorders, especially Alzheimer’s neuropathology [7].
Individuals with DS occasionally develop the myeloproliferative disorder 
(TMD), a disease that is mostly unique to DS. Almost all TMD cases were found to 
contain somatic mutations on the X chromosome, in the GATA1 transcription factor 
[8]. Certain features of DS contain genes on other chromosomes causing gene and 
trisomy mutations and working together to reveal the disorder in HSA21. Studies 
have shown that the formation of Trisomy 21 precedes the formation of GATA1 
mutations [1]. This may indicate that Trisomy 21 either increases genomic discrep-
ancy leading to GATA1 mutations, or it supplies a selected medium for hematopoi-
etic cells containing GATA1 mutations.
1.1.2 Molecular mechanism
Many hypotheses have been proposed to explain the genotype–phenotype relation-
ship in DS. One of these is the ‘gene dosage effect’ hypothesis putting forward that 
the phenotypes arise directly from the dosage imbalance of the genes. Overlapping 
this hypothesis, the ‘DS Critical Region’ (DSCR) was announced in the 1990s. [9, 10]. 
Many of the DS features can be called into a subset of the critical genes in the DSCR 
region, suggesting that DS phenotypes are mainly caused by the dosage imbalance 
of only a few genes on HSA21. Genomic regions affecting the presence of certain DS 
phenotypes have been identified and high-resolution genetic maps of DS features have 
been created [11]. Olson et al. studied the DSCR regions in mice to test its hypothesis. 
They concluded that dosage imbalance of some individual genes on HSA21 directly 
affects certain phenotypes, but they stated that more studies are needed [12].
The “amplified developmental instability” hypothesis suggests that dosage 
imbalance of the HSA21 gene leads to a non-specific impairment of cellular homeo-
stasis [10]. Extra chromosome materials may also contribute to phenotypes by 
disrupting chromosomal regions. Some data on monozygotic twins for TS21 suggest 
that differential expression between normal and trisomic twins can be regulated 
across chromosome domains. This study shows that some DS phenotypes can be 
enlightened by the modification of the chromatin structure in the nucleus [13]. 
Monozygotic twins affected by DS but showing incompatible phenotypes have been 
reported in some cases, suggesting the role of epigenetics in the phenotypic vari-
ability of DS. For example, DNA methylation (controlling gen expression) has been 
shown to change in Trizomy of chromosome 21 (TS21) samples [14].
1.1.3 Turner syndrome
Turner syndrome (TS) is a disorder in mosaic karyotypes associated with 
complete or partial loss of the X chromosome. Seen especially in women, TS is 
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associated with short stature, delayed puberty, ovarian dysgenesis, infertility, 
congenital malformations of the heart, type 1 and type 2 diabetes mellitus, osteopo-
rosis, and autoimmune disorders. It occurs in almost every 2500 live female births. 
Fetuses affected by TS are 99% estimated to result in fetal death. Approximately 
half have monosomy X (45, X) and 10% have a repeat (isochromosome) of the long 
arm of the X chromosome. Most of the rest has a mosaic in more cell lines for 45X. 
TS, which is associated with a missing X chromosome, was first identified about 
100 years ago [15].
Related genes: Shox gene (short length homeobox protein-coding) located on 
X and Y chromosomes, it is a gene responsible for TS phenotype. This gene does 
not undergo X inactivation, and a decrease in the expression of SHOX explains 
some of the TS-related growth deficits. The gene product controls the expression 
of natriuretic peptide B (NPBB) and FGFR3 (fibroblast growth factor receptor 3) 
and regulates the proliferation and of chondrocytes, and also cooperates with SOX5, 
SOX6 and SOX9 and some other genes [16].
The TS genome is hypo-methylated with less hypermethylation sites and there 
are RNA expression changes that affect the X chromosome genes and autosomal 
genes compared to women who are 46 XX. Known escape genes are expressed 
differently in individuals with TS and other X chromosome genes such as RPS4X 
and JPX (CD40LG and KDM5C) in particularly, KDM5C (encoding lysine-specific 
demethylase 5C) can participate in the transcriptional profile of neuronal genes and 
play role in different neurocognitive profiles [17]. 40S ribosomal protein S4 (RPS4X) 
also plays an important role in TS, bringing together multiple protein complexes. In 
addition, the Y paralog of RPS4X (RPS4Y) may also have a role since it is normally 
expressed as duplicates [18].
Many different studies show that women with TS have increased mortality 
compared to the pool of a wide variety of related diseases [19]. The most obvious 
increase in morbidity is caused by autoimmunities like diabetes mellitus or thy-
roiditis, osteoporosis, cardiovascular diseases, hypertension, congenital malforma-
tions, especially endocrine diseases including heart diseases, digestive system and 
anemia [20].
1.1.4 Genotype-phenotype
It is still unclear which chromosomal regions or genes make up the phenotypi-
cal properties of TS. The physical symptoms of TS were thought to be due to the 
absence of normal sex chromosomes before inactivation of the X chromosome, or 
the haplo-insensitivity of the genes in the pseudo-autosomal regions of the aneu-
ploidy [21]. It is thought that a complete phenotype results in the loss of short arm 
(Xp) in the X chromosome. Aneuploidy itself can cause growth failure. Loss of a 
region in Xp22.3 was found to be related to neurocognitive problems in TS [22]. Loss 
of the SRY gene locus in the short arm of the Y chromosome leads to the phenotype 
of TS, even if it does not cause a population of 45 X cells. It has also been suggested 
that an area in Xp11.4 is important for the development of lymphedema [23].
1.2 Cellular proliferation: cancer
Cancer can be defined as the uncontrolled cell growth with the most basic expla-
nation. Cell stacks that grow uncontrollably are called tumors. Benign tumors grow 
much slower and usually do not metastasize, while malignant tumors can spread to 
other organs through metastasis, and lead to multiple organ damage and eventu-
ally death. Tumor cells acquire characteristic features such as sustaining growth 
signals in the process of cancer, avoiding growth suppressors, resisting cell death, 
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ensuring replicative immortality, initiating angiogenesis, and activating invasion 
and metastasis [24].
Cancer cells acquire these abilities in the process due to genetic instability 
and inflammation caused by environmental and hereditary effects. Many studies 
show that viruses, in addition to many environmental factors such as radiation 
and chemicals, induce cancer. Chronic inflammation has been shown to trigger 
oncogenic mutations, genetic instability, tumor growth, and angiogenesis through 
angiogenesis and cause local immunosuppression [25].
Two types of gene groups involved in cancer are oncogenes, which trigger cel-
lular growth and uncontrolled proliferation, causing increased genetic instability 
with increased expression and tumor suppressor genes that cause cancer as a result 
of decreased control of their expression, cell division, and growth. Proto-oncogenes 
include RAS, WNT, MYC, ERK, and TRK genes. A mutation that may occur on 
a proto-oncogene or a regulatory region of the gene (e.g., promoter region) can 
cause an increase in the amount of protein with the change in protein structure 
[26]. Expressions of oncogenes can also be regulated with miRNAs [27]. Mutations 
occurring in these regulatory miRNAs can cause activation of oncogenes [28]. 
Cancer cells increase cell growth-division by activation of oncogenes, as well as 
suppress preventive control mechanisms of tumor suppressor genes that control 
this process.
Mutations in tumor suppressor genes cause loss of function. Therefore, they 
occur in both alleles. To inactivate the gene and its protein, wide-ranging effects, 
such as deletions, frame-shift mutations, insertions, should be seen rather than 
point mutations [29]. Tumor suppressor genes include retinoblastoma (RB) [30], 
TP53, BRCA1, BRCA2, APC, and PTEN. Many side factors such as transcription 
complexes, changes in cellular metabolism, microenvironment can guide the course 
of cancer [31].
The development of cancer is a multi-stage process consisting of initiation, 
promotion, and progression. Cancer-inducing events are usually caused by genetic 
mutations. Mutant cell proliferates rapidly in the promotion stage and acquires 
features that allow malignant behavior in the progression stage. Production of 
telomerase and expression of p53 are examples of malignant behavior [32]. Then, 
the process proceeds in the form of dysplasia formation, where new blood vessels 
are formed (angiogenesis) with cellular transformation. Angiogenesis facilitates the 
intravasation of cancer cells after undergoing an epithelial-mesenchymal transi-
tion (EMT) [33]. EMT gives an invasive phenotype to cancer cells and is managed 
by various transcription factors (such as SNAI, SLUG, ZEB2, ETS1, TWIST) [34]. 
These transcription factors also regulate each other for the protection of EMT [35].
1.2.1 Cancer cell metabolism
Normal cells only use anaerobic glycolysis when oxygen is absent or limited, 
while cancer cells can convert glucose to lactate in the presence of oxygen. Otto 
Warburg discovered that cancer cells exhibit a differentiated metabolism abil-
ity [36]. Warburg effect is biochemical properties that help identify cancer cells. 
On the other side, cancer cells are generally highly glucose-dependent. Glucose 
intake of cells is enabled by overexpression of different isoforms of membrane 
glucose transporters in cancer cells [37]. It has been shown that the benefit of the 
Warburg effect for cancer cells is not just the formation of glycolytic ATP, but also 
the production of many glycolytic intermediates before anabolic processes such as 
NADPH and amino acids [38]. Cancer cells are also able to metabolize glutamine to 
synthesize some amino acids they need, use it as a nitrogen source and for fatty acid 
synthesis in hypoxic conditions [39]. Therefore, blood glutamine levels increase 
5
Molecular Mechanisms of Distinct Diseases
DOI: http://dx.doi.org/10.5772/intechopen.95114
in some cancer cases [40]. Lactic acid is used to produce citric acid and maintain 
cancer progression in neighboring cancer cells. This is called the “Reverse Warburg 
effect” [41].
Tumor micro-environment, consisting of fibroblasts, adipocytes, endothelial 
cells, and macrophages, is a good source for tumor growth. Tumors “steal” energy-
rich metabolites from their micro-environment [42]. Monocarboxylate carriers 
(MCTs) are used for L-lactate transfer between cancer cells and their microenviron-
ment [43]. Tumors have heterogeneous structures with hypoxic and aerobic regions. 
A “metabolic symbiosis” behavior has recently been found between the two regions 
[44]. Lactate is produced by glycolysis in hypoxic tumor cells. This product is 
obtained by aerobic cancer cells by MCT1. Aerobic cells convert lactate to pyruvate 
with lactate dehydrogenase isoform B (LDH-B) enzyme.
When glucose consumption is not enough to meet the energy need of cancer 
cells, they begin the fatty acid oxidation (FAO) [45]. For example, prostate cancer, 
leukemia, and large B-cell lymphoma, increasing palmitate and FAO uptake in cells 
are among the most commonly used bioenergetic pathways [46–48]. Normal cells 
usually receive fatty acids by diet, while tumors show an increase in de novo fatty 
acid synthesis [45].
Pyruvate plays a pivotal role in the regulation of metabolic reprogramming, 
especially in tumors [49]. Pyruvate dehydrogenase (PDH) converts cytosolic pyru-
vate into mitochondrial acetyl-CoA, which is the first substrate of the Krebs cycle. 
Pyruvate dehydrogenase kinase (PDK) negatively regulates PDH. This reaction 
slides glucose from oxidative to glycolytic metabolism [50]. Lactate dehydrogenase 
(LDH) is the primary metabolic enzyme converting pyruvate into lactate. LDH 
plays an important role in arranging food interchange between stroma and tumor. 
Studies have shown that inhibition of LDH is important for treating advanced 
carcinomas [51]. Mitochondrial hyperpolarization is a mutual property of several 
tumor cells [52]. Tumor cells, which have more negative mitochondrial structures, 
are more selective targets in drug therapies [53].
1.2.2 Brain cancer
Brain tumors are cancer tissues that grow abnormally and prevent the brain or 
central spinal system from performing its normal functions. Primary brain tumors 
originating from brain tissue can usually spread only to other parts of the brain, and 
occasionally to other organs. Tumors that form in another tissue in the body migrate 
to the brain are called metastatic or secondary brain tumors. These types of tumors 
occur more frequently than primary brain tumors. They are termed after their 
tissue of origin [54].
The most prevalent primary tumor types in adults are glioma, astrocytomas, 
oligodendroglioma, meningioma, schwannoma, pituitary tumors, and central 
nervous system (CNS) lymphoma.
1.2.3 Genetic background of brain cancer
Retinoblastoma mutations are found in almost 75% of brain tumors and are 
mostly associated with glioblastoma, and Tp53 mutations are found in more 
than 80% of advanced gliomas [55]. Primary glioblastomas have EGFR tyrosine 
kinase mutations, tumor suppressor PTEN gene mutations, DNA repair protein 
O6-methylguanine-DNA methyltransferase (MGMT) protein abnormalities [56, 
57]. While IDH1 mutations in the control mechanism of the citric acid cycle are 
seen in advanced glioblastomas, IDH2 mutations are usually shown in oligo-
dendroglioma [58]. Mutations in the BRAF oncogene are common in pilocytic 
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astrocytomas, pleomorphic xanthoastrocytomas, and gangliogliomas [55]. In 
some glioblastoma tumors, telomere length is maintained by mutations in the 
TERT promoter and ATRX gene [59].
WHO groups glioma patients based on the presence of two genetic changes; 
first, mutations [60] in the family of genes encoding isocitrate dehydrogenase 
(IDH), and second, loss of two specific parts of the genome (1p and 19q co-dele-
tion) [61]. The presence or absence of these changes gives a clue about the patient’s 
prognosis and appropriateness of various kinds of treatments.
Approximately 40% of people with astrocytoma, oligodendroglioma, or IDH 
mutation bear a hereditary variation. This variation is a single nucleotide polymor-
phism (SNP) in the 8q24 region of the genome [62]. There is another SNP in the 
11q23 region, which enhances the risk of IDH-mutant brain cancer. Approximately 
5–8% of gliomas are familial, POT1 gene mutations have been found in 6 of 300 
families with glioma [63].
Non-coding RNAs (ncRNAs) play important roles in regulating tumor malignancy 
in glioma [64–66]. According to healthy brain tissue, mir-21 expression increases 
in glioma and mir-21 acts as an oncogene [67, 68]. It has been reported that mir-124 
and mir-137 act as tumor suppressors in glioblastoma multiform cells [69]. Hotair, 
SOX2ot, CRNDE, Malat1, H19, GAS are lncRNAs that have been recently shown 
to regulate glioma [70, 71]. Glioma cells also express the circRNAs, for example, 
circBRAF, bircFBXW7, circSMARCA5. These regulate proliferation, migration, and 
invasion of glioma cells [72–74]. The exosomal ncRNAs, mir-21, mir-148a, lncRNA 
PU03F3, lncRNACCAT2 can be used as circulating biomarkers of glioma patients 
[75–78]. circRNAs and the exosomal ncRNAs were also reported as potential biomark-
ers for the diagnosis and prognosis of glioma patients.
1.3  Molecular pathology of neurodegenerative diseases with Alzheimer’s 
disease in focus
As a characteristic of almost all neurodegenerative diseases, abnormal protein 
assembly gathers these diseases under the prion concept [79]. Prion protein, known 
as PrP, was introduced to define protein pathogens and distinguish them from 
viruses and was identified as a proteinaceous infectious particle known to resist 
inactivation. Even back at that time, its importance was foreseen in terms of shed-
ding light on the etiologies of chronic degenerative diseases [80]. Self-propagation 
is an important characteristic of prions that is also observed in abnormal protein 
assembly in Alzheimer’s Disease (AD) [81, 82]. Aggregation of proteins in neuro-
degenerative diseases was believed to occur spontaneously in autonomous cells, 
however, it was later understood that this aggregation begins in a particular region 
and propagates across other regions developing the disease further. Transmission of 
these prion proteins across neuronal cells takes place trans-synaptically [82].
As described more than a 100 years ago, abnormal protein assembly forms the 
basis of neurodegeneration with AD being one of the most common neurodegen-
erative diseases. The pathology of abnormal protein assembly starts with misfolding 
of native proteins that gather to form seeds which eventually lead to aggregation 
and development of protein fibrils. The pathophysiology of AD involves amyloid 
plaque inclusions of β-amyloid (Aβ) peptides and neurofibrillary lesions of tau pro-
tein. Tau inclusions may also be characteristics of other neurodegenerative diseases, 
which do not necessarily show the same implications. Altering the native forms of 
this protein may contribute to its pathology and cause damage to its host cell.
Most cases of this disease are sporadic, while dominantly inherited mutations 
are also seen to a lesser extent. Back in the 1990s, missense mutations of APP, 
encoding amyloid precursor, were shown to cause AD [83–87]. Mutations in this 
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gene also increase the aggregation tendency of encoded proteins. Many studies have 
demonstrated phenotypes associated with neurodegeneration when this protein is 
overexpressed.
There are six isoforms of microtubule-associated protein tau ranging from 352 
to 441 amino acids, encoded by the MAPT gene as a result of alternative mRNA 
splicing. One half has three repeats and the other has four repeats, altogether 
establishing the microtubule-binding domain and also the core of tau filaments 
in case of pathology [88]. All isoforms have been observed in the brains of AD 
patients. Diseases that have isoforms with only three or four repeats, but not both, 
lack the Aβ peptides seen in AD and therefore do not carry the symptoms specific 
to the disease [70]. Tau inclusions may be of a variety of conformations, which can 
also be caused by different mutations on the MAPT gene, explaining the existence 
of numerous tauopathies [89–93].
Aβ peptides are encoded by the amyloid precursor protein gene, APP, and are 
widely expressed as type 1 transmembrane glycoproteins. As a result of alterna-
tive mRNA splicing, there are three major transcripts named APP695, APP751, 
and APP770 [94, 95]. β- and γ-secretase enzymes take part in the production of 
Aβ peptides in sequential endoproteolytic cleavage. β-secretase is responsible for 
cleaving the N-terminus of the peptide thus removing the portion that remains on 
the extracellular side. This cleaved peptide is endocytosed and intracellular aggrega-
tion builds up which is later released into the extracellular space [79]. γ-Secretase is 
a membrane-embedded enzyme that is able to cleave many transmembrane proteins 
including C-terminus of the Aβ peptide. It a complex enzyme of four proteins; 
presenilin (PS) forming the catalytic core, presenilin enhancer-2 (Pen-2) enabling 
maturation of PS, anterior pharynx-defective (Aph-1) stabilizing the complex, and 
nicastrin possibly being the receptor for the enzyme’s substrate [96, 97]. PS and 
Aph-1 each have two variants resulting in at least four different enzyme complexes, 
which give rise to various cleaved Aβ peptides. Additionally, γ-secretases cleave 
the peptide in three different sites. Different protein variants and cleavage sites 
produce Aβ peptides of different profiles, some of which may be more susceptible to 
 aggregation [98].
Overall, it is important to target the pathways leading to abnormal protein 
assembly and only then treatments may be proposed based on these mechanisms. 
Once the first protein inclusion is formed, it is essential to keep an eye on the time 
frame until the disease symptoms come forth. When techniques sensitive enough to 
catch the first protein inclusion are developed, then tracking its transformation into 
filaments can be helpful in designing novel preventive approaches. Understanding 
this cascade will also contribute to planning more efficient therapeutic methods.
1.4 Cellular and molecular mechanisms of asthma and COPD
Asthma and chronic obstructive pulmonary disease (COPD) are common 
disorders characterized by progressive chronic inflammation in the lungs. They 
have unique characteristics with dissimilarly involved cells, mediators, and inflam-
mation. They also have distinct responses to corticosteroid treatment. Roughly 15% 
of COPD patients have characteristics of asthma [99]. Also, a comparable ratio of 
asthma patients has traits of COPD that is currently the fifth leading cause of death 
worldwide [100]. Many risk factors are linked to COPD including smoking tobacco, 
air pollution, indoor cooking while tobacco smoking (including passive smoking) 
making up around 80% of the cases [101]. There are many types of cells and media-
tors that have a significant effect during the pathogenesis of asthma and COPD.
Macrophages have a crucial role in coordinating the inflammatory response acti-
vated by cigarette smoke extract in COPD cases [102]. They discharge inflammatory 
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mediators including tumor necrosis factor (TNF)-α, IL-8, other CXC chemokines, 
monocyte chemotactic peptide (MCP)-1, LTB4 and reactive oxygen species (ROS) 
[103]. However, the role of macrophages in asthma is not certain. Allergens via 
low-affinity IgE receptors may activate macrophages causing an inflammatory 
response through the discharge of a definite arrangement of cytokines. On the other 
hand, macrophages also excrete anti-inflammatory mediators, such as IL-10 that is 
thought to decrease in subjects with intense asthma [104].
Activated neutrophils were shown to be enhanced in some subjects with severe 
asthma and COPD in their sputum and airways [105]. Among the serine proteases 
secreted by neutrophils are neutrophil elastase (NE), cathepsin G, proteinase-3, 
matrix metalloproteinase (MMP)-8 and MMP-9, leading to alveolar destruction 
[103]. The mechanisms of neutrophilic inflammation in asthma and COPD are not 
clear. Demonstration of priming in COPD occurs at neutrophils in the peripheral 
circulation. Many chemotactic signals exhibit the capacity for neutrophil recruit-
ment in COPD. These include LTB4, IL-8 and related CXC chemokines, comprising 
GRO-α (growth-related oncoprotein) and ENA-78 (epithelial neutrophil activat-
ing protein of 78 kDa) which are enhanced in COPD airways [106]. Although the 
mentioned mediators might be sourced from alveolar macrophages and epithelial 
cells, neutrophils have the capacity of being a vital source of IL-8 [107].
Airway and alveolar epithelial cells in COPD can be a vital point of source of 
inflammatory mediators and proteases 5. Cigarette smoke activates epithelial cells 
which produce inflammatory mediators, including TNF-α, IL-1β, GM-CSF and 
IL-8 [108]. Epithelial cells play an important role in airways defense and tissue 
repair processes. Goblet cells, a type of epithelial cell, in mucus catch bacteria and 
inhaled particulates [109]. Epithelial cells release antioxidants and antiproteases. 
Immunoglobulin A is carried by epithelial cells, hence involved in adaptive immu-
nity [110]. On a side note, native and adaptive immune reactions of the airway 
epithelium are triggered by cigarette smoke and damage by other harmful agents, 
increasing sensitivity to infection.
The main role of dendritic cells is to introduce innate and adaptive immune 
reaction by activating macrophages, neutrophils, T and B lymphocytes among 
others [103].
Lymphocytes are directly involved in the pathogenesis of both asthma and 
COPD. Both airway and parenchymal inflammation exist in asthma and COPD 
patients [111]. Most lung lymphocytes are T cells which are in the respiratory tract 
of ordinary humans. Activated T lymphocytes are characteristic in both asthma 
and COPD, but CD4+ type-2 T lymphocytes are the major player in asthma whereas 
CD8+ type-1 lymphocytes are specific to COPD [111]. CD4+ T lymphocytes can 
generate many cytokines involved in mediating cell functions and cell–cell com-
munications. This is done through impressing physiologic cell properties such as 
proliferation, differentiation and activation of other immunocompetent cells, 
chemotaxis, and connective tissue metabolism [112]. On the other hand, CD8+ T 
lymphocytes exist in the respiratory mucosa and are activated in response to foreign 
antigens [111]. Specifically, the cells in the respiratory mucosa have an important 
role in anti-viral immunity. Another lymphocyte type is B cells which are the 
minority (<5%) lymphocytes. The main function of B cells located in the lungs is 
the production of immunoglobulins for local defense mechanisms [113].
Apart from these mentioned cells, there are crucial molecular mediators in the 
pathogenesis of asthma and COPD. The first family of mediators is transform-
ing growth factor (TGF) family. The TGF-β subfamily is composed of five parts 
that exhibits plenty of effects pertaining to asthma and COPD. A recent study 
shows that overexpression of TGF-β1 in mice causes Smad3-dependent pulmo-
nary expression of procollagen, antiproteases and fibrosis [114]. TGF-β exhibits 
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chemotactic signatures for monocytes, macrophages and mast cells. Research shows 
an abnormal pulmonary expression of TGF-β1 in subjects suffering from COPD. 
Protein and mRNA expression of TGF- β1 are abundant in the lung tissue, including 
airway epithelial cells, of mild to moderate COPD patients. TGF-β1 has the role in 
pathogenesis of COPD because of its increased expression in parallel to the number 
of macrophages [115].
Another mediator family is the fibroblast growth factor (FGF) family with 23 
members in humans. Their functional receptors are named from FGFR1 to FGFR5 
[116]. FGFs have many functions such as development, tissue homeostasis, and 
repair. In addition to further growth factors, FGF-1, FGF-2, and FGF-7 and their 
receptors FGFR1 and FGFR2, are located abundantly in the lungs [101]. Research 
shows that increased expression degrees of FGF-1, FGF-2, and FGFR1 were 
detected in vascular and epithelial areas in the lungs of COPD patients. FGF-1 
causes higher collagenase expression and lower collagen I expression in lung 
fibroblasts which prompt tissue remodeling.
Another family of mediators is the vascular endothelial growth factor (VEGF) 
family. There are seven units in this family capable of attaching to related cellular 
receptors. VEGFs have many functions including paracrine acting, angiogenic 
factors, prompting mitogenesis, emigration, and permeabilization of the vascular 
endothelium [101]. VEGF and its receptors assist in tissue remodeling as well as dis-
ease intensity in incessant lung diseases such as asthma [117]. COPD patients have 
increased pulmonary VEGF expression in bronchial and alveolar epithelial located 
around the vascular smooth muscle and alveolar macrophages. Additionally, unlike 
healthy subjects, COPD patients exhibit elevated levels of VEGFR-1 and VEGFR-2 
expression inside the endothelium [118]. Furthermore, VEGFR-2 and VEGF 
expressions are decreased in COPD patients. Compared to VEGFR-2, VEGFR-1 has 
a higher affinity for VEGF which leads to VEGFR-1 scavenging VEGF from VEGFR-
2. This phenomenon culminates VEGFR-1 activation and in the case of endothelial 
apoptosis, increased MMP activity as well as vascular and alveolar decimation [101]. 
This suggests the importance of harmony among VEGF, VEGFR-1, and VEGFR-2 
during the pathogenesis of COPD subordinary types.
Finally, cytokines and chemokines are mediators supplying a chemotactic gradi-
ent which has the potential to activate macrophages, CD8+ T cells and neutrophils 
for COPD patients. It is known that inflammatory cells of both native and gained 
immune systems are significant in the COPD pathophysiology. This is where cyto-
kines and chemokines are the key drivers [103, 119]. Different types of cytokines 
arrange chronic inflammation in asthma and COPD. T2 cytokines which are IL-4, 
IL-5, IL-9 and IL-13 interfere with allergic inflammation. Other types of cytokines 
including TNF-α and IL-1β accelerate the inflammatory response [120]. In asthma 
and COPD patients, chemokines are instrumental in drawing inflammatory cells 
from the circulation into the lungs [121].
1.5 The endocrine system
1.5.1 Molecular mechanism of obesity and obesity-induced insulin resistance
Obesity is a serious health problem that has become epidemic all over the world, 
especially in developed countries. It is characterized by hypertrophied adipocytes 
that secrete various adipokines and hormones, chronic inflammation in all tissues, 
and systemic insulin resistance resulting in type 2 diabetes, hypertension, and 
hyperlipidemia. In addition to these metabolic diseases, it can cause diseases such 
as cancer, atherosclerosis, obstructive sleep apnea syndrome, steatohepatitis, and 
musculoskeletal problems [122]. The obesity rate is 20% in women and 18% in men 
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in developed countries [123]. It affects complex metabolic pathways in all tissues 
as a result of chronic and progressive inflammation, leads to insulin resistance, 
endothelial dysfunction and lipotoxicity.
The pathophysiology of obesity includes complex interactions of numerous 
adipokines, hormones and pro-inflammatory cytokines with the central nervous 
system and metabolic organs (such as liver, pancreas, and muscle) as a result of 
genetic-environmental interactions.
Genetic etiology: Obesity is generally present in a polygenic etiology. Many 
studies have investigated the genetic background of body mass index (BMI) and 
waist/hip ratio (WHR), which are the best measurements of obesity. The results of 
these studies have been presented collectively in genome-wide association stud-
ies (GWAS) [124]. Although, single gene defects (monogenic) are rare in obesity, 
including especially melanocortin-4 receptor, leptin and leptin receptor genes [125].
Dysregulation in hypothalamic control: The center of food intake and energy 
regulation in the central nervous system is the arcuate nucleus (ARC) in the hypothal-
amus besides the autonomic nervous system and brain stem. The balance between the 
opposing effects of orexigenic and anorexigenic neurons is important. Agouti-related 
protein (AgRP) and neuropeptide Y (NPY) (AgRP/NPY) neurons are orexigenic that 
promotes appetite and eating. Pro-opiomelanocortin–producing (POMC) peptide 
and cocaine-and-amphetamine–regulated transcript (CART), collectively known as 
POMC/CART neurons are anorexigenic that suppress appetite and eating. Oxygenic 
pathways that increase energy balance become more effective in obesity [126].
Adipose tissue dysfunction and systemic inflammation; The most important 
pathophysiological mechanisms of obesity and obesity-related insulin resistance 
are adipocyte dysfunction (visceral adipose tissue; VAT) and low-grade chronic 
systemic inflammation. In particular, white adipocyte tissue in obese subjects 
contributes to the regulation of food intake, energy metabolism and other functions 
by secreting adipokines from adipose tissue, which provide the necessary signals to 
the central nervous system, hypothalamus, liver, pancreas, muscle tissue, and other 
systems to regulate appetite, food intake, and energy balance [125]. Leptin is the 
most important adipokine that stimulates anorexigenic POMC/CART neurons and 
induces production of pro-inflammatory cytokines (TNF-alpha and IL-6) by mac-
rophages and monocytes. In the case of hyperleptinemia, leptin resistance develops 
by the inhibition of the JAK2/STAT3 signaling pathway, which later increases 
oxidative stress and inflammation, causing insulin resistance, hyperlipidemia and 
hypertension [127]. Resistin is a pro-inflammatory adipokine produced by the 
resistin gene (RETN), which activates SOCS3, causing the insulin signaling pathway 
to be inhibited and consequently induces insulin resistance [128]. Other adipokines 
like Retinol binding protein 4 (RBP4), Angiopoietin-like protein 2 (ANGPTL2), 
Visfantin, Adiponectin, Lipocalin 2, Serum Amyloid A, Angiotensinogen, Renin, 
Angiotensin-Converting Enzyme, Acylation-Stimulating Protein, and Vaspin, are 
increased, and adiponectin, and Apelin are decreased in obesity, altogether stimu-
lating inflammation, lipolysis, releasing free fatty acid (FFA) and causing insulin 
resistance as a result [129].
Gastrointestinal hormones and microbiota: Gastrointestinal hormones and 
gut microbiota play a significant role in the complex pathophysiology of obesity. 
Ghrelin produced in the stomach induces starvation and food intake by stimulating 
orexigenic AgPR/NPY neurons in the hypothalamus. Although the effect of ghrelin 
cannot be fully explained, it is thought to increase in obesity, stimulate growth 
hormone release (GH), increase gastrointestinal motility and insulin secretion 
[130]. Decreased GLP-1, Peptide YY, pancreatic polypeptide, and increased amylin 
and cholecystokinin cause appetite inhibition and gastric emptying delay, resulting 
in excess energy [129]. Besides hormones in the gastrointestinal tract, changes in 
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microbiota-gut-brain axis and their effects on metabolic organs are also important. 
Occurring as a result of nutrition and gene–environment interactions; chronic 
systemic inflammation resulting from intestinal microbiota dysbiosis (increase in 
Firmicutes-Bacteroides ratio), microbial fermentation products, increase in short-
chain fatty acid formation and intestinal permeability, decrease in butyrate-pro-
ducing bacteria rate, leads to an increase in proinflammatory response in metabolic 
organs, impaired fat metabolism and glucose metabolism [131, 132].
İmpaired insulin sensitivity and oxidative stress; The beginning of insulin 
resistance is the first step in the pathophysiology of T2D. Anabolic effects such 
as glycogen and protein synthesis, glucose transport, adipogenesis are formed by 
phosphatidylinositol-3-kinase (PI3K)/Akt pathway activation as a result of insulin 
binding to its receptor (INSR) synthesized in the pancreas [133]. On the other hand, 
insulin shows mitogenic effects with mitogen-activated protein kinases/Ras path-
way (MAPK/Ras).
Adipokines, FFA’s, pro-inflammatory cytokines (TNF-a, IL-18, IL-1β, IL-6), syn-
thesized as a result of inflammation in adipose tissue in obesity, also cause systemic 
inflammation in metabolic tissues such as liver and muscle. As a result, decreased 
GLUT-4 expression, activation of Ser/Thr kinases with insulin receptor substrate 
(IRS) phosphorylation, production of ceramides and proinflammatory cytokines, 
suppressing of cytokine signaling-3 (SOCS-3) expression, insulin pathways and 
effects. On the other hand, increased production of reactive oxygen radicals and 
production of toxic doses NO with inducible nitric oxide synthase (iNOS) activation, 
affect mitochondrial and endoplasmic reticulum functions. Activation of pro-inflam-
matory pathways increased oxidative stress, mitochondrial dysfunction, ER stress 
affects lipid metabolism, insulin mechanisms of action and other metabolic pathways, 
causing insulin resistance, Type 2 diabetes, hypertension, and hyperlipidemia [134].
Beta-cell dysfunction: In addition to peripheral insulin resistance in obesity, 
serious reductions in beta cell function are also observed. An increase in fat accu-
mulation in islet cells due to chronic lipotoxicity disrupts the function of beta cells 
by blocking calcium channels. Chronic hyperglycemia due to disruption in glucose 
metabolism and systemic inflammation due to an increase in oxidative damage 
and lipotoxicity, disrupt insulin secretion pathways and cause changes in apoptosis 
gene expression. Hyperinsulinemia in obesity, impaired insulin signaling pathway, 
oxidative stress, lipotoxicity in islet cells, loss of beta-cell function and apoptosis 
may lead to the formation of type 2 diabetes [122, 135].
Obesity has become a pandemic all over the world as a result of rapidly changing  
lifestyles and genetic heritage in the last century. Despite the findings in recent 
studies on the development and complications of obesity, it is difficult to say that 
the subject of etiology and pathophysiology is still not fully understood. Especially 
omics technologies, big data on environmental gene interactions, neuroendocrinol-
ogy, and neuropsychological studies will reveal findings that open up different 
horizons. However, due to its complications from deadly metabolic diseases to 
cancer, rapid preventive measures should be taken, and effective treatment models 
should be developed.
1.6 Alterations of blood cells: lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) is a heterogeneous malignancy emerging 
from lymphoid precursors. It is characterized by the proliferation of immature 
lymphoid cells with somatic mutations including chromosomal rearrangements, 
and aneuploidy [136]. ALL has two peak points; first point occurs at ~5 years of 
age (80%), and the second point occurs at the age of ~50 (20%) [137]. The basic 
mechanism underlying the development of ALL is similar in children and adults, 
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while they have the frequency of different genetic subtypes. Molecular analysis of 
genetic changes in leukemia disease provides a great advantage in order to under-
stand prognosis and pathogenesis of ALL [138].
The diagnosis of ALL depends on the presence of at least 20% lymphoblast 
in bone marrow. Immunophenotyping by flow cytometry (FCM) identifies the 
subtype of ALL that may be B-cell precursor (BCP), mature B-cell types, or 
T-cell ALL. Chromosomal abnormalities are a characteristic of lymphoblastic 
leukemia, which are found in B or T cell lineage. The most common abnormality 
found in adult B precursor ALL is the t(9;22) BCR-ABL translocation, while the 
t(12;21)(p13;q22) TEL-AML1 translocation is most commonly found in child-
hood B precursor ALL [139]. On the other hand, the discovery of mutations in 
the receptor tyrosine kinase FLT3 contributes to the understanding of leukemo-
genesis mechanism in hyperdiploid ALL (20% of cases). Based on this finding, 
targeting specific tyrosine kinase inhibition may be useful in the management of 
leukemia [140].
1.6.1 Treatment in patients with lymphoblastic leukemia
Small-molecule kinase inhibitors have a clear benefit in the treatment of many 
cancer types including leukemia. Imatinib mesylate, a small-molecule inhibitor 
of BCR-ABL kinase, is highly effective in the treatment of chronic myelogenous 
leukemia (CML) [141]. Although the single kinase inhibitor is a remarkable treat-
ment option in a different type of leukemia, it will need to be combined with either 
other targeted therapy or chemotherapy because of the resistance to small-molecule 
inhibitor [142]. Unlike ALL, Chronic Lymphocytic Leukemia (CLL) is defined the 
accumulation of monoclonal B cell with a special immunophenotype in the bone 
marrow, blood, and other lymphoid organs where B lymphocytes express CD19, 
CD23, CD5, low-level CD20 and surface immunoglobulins [143]. The standard 
treatment procedure of ALL and CLL includes consolidation therapy following 
chemotherapy in pediatric patients. For adult patients, unlike pediatric patients, 
the allogeneic hematopoietic stem cell transplantation is frequently preferred as 
consolidation therapy [144]. Because the patients resistant to chemotherapy are 
not respond to treatment well enough, novel therapy approaches such as Chimeric 
antigen receptor-modified T cell (CAR-T) therapy have developed in order to 
overcome chemotherapy resistance and improving the outcome of patients [145]. 
CAR-T cells, as immunotherapeutic tools, are genetically engineered to express a 
chimeric antigen receptor recognizing an antigen that is located in the special cells 
such as a tumor [146]. CD19 antigen on B lymphocytes was considered the initial 
target for CAR-T cell therapy. However, specific antigen loss might cause the failure 
of CAR-T cell therapy in CLL. CD19–20 co-targeting CAR-T cells were designed to 
kill both CD19-positive and CD19-negative CLL and it was shown that these cells 
were very effective in killing CLL cells. In one of the first reported in pediatric ALL 
the clinical trials, CAR-T cells targeted the CD19 antigen of B cells are designed with 
CD3ζ and CD28 costimulatory domain [147].
1.7 Viral immunology and infectious diseases
1.7.1 The differences between HIV-1 and SARS-CoV-2 genome
The origin of a pathogen has a crucial role in developing vaccines and block-
ing transmission. This may last many years due to its elusiveness as seen in HIV-1, 
SARS, and MERS [148–150]. According to a recent report, it was emphasized that 
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SARS-CoV-2 is able to infect T cells, which are targeted by HIV [151]. Another 
report alleged that the motif insertions of spike glycoprotein, similar to HIV-1, may 
help increase the range of host cells of SARS-CoV-2. HIV-1 envelope glycoprotein 
contains mutable insertions and deletions not necessary for biological function. 
Only 1 and 2 insertions are matched in only a few HIV-1 strains and this reveals that 
four insertions are scarce. Thus, HIV-1 cannot be assumed as the source for those 
insertion sequences in the SARS-CoV-2 genome due to their inefficient identities 
and scarceness in the HIV-1 sequences [152].
1.7.2 The origin of SARS-CoV2
The reported cases showed that there have been 3,162,284 COVID-19 cases in 
at least 212 countries and approximately 7.1% of which was resulted in death as of 
April 30, 2020 [153]. It is known that SARS-CoV, MERS-CoV, and SARS-CoV-2 are 
the members of coronoviridae family of the Nidovirales order, which comprises a 
relatively positive-sense, single-stranded RNA genome of around 26–32 kb [154]. 
5o-methylguanosine cap at the beginning, a 3o-poly-A tail at the end, and a total of 
6–10 genes in between exist in their genome [155, 156].
This family has extremely expressive instability and recombination rate, which 
is similar to RNA viruses, so it is practically unfeasible to prevent their distribu-
tion among humans and animals worldwide; nevertheless, the fact that the virus is 
exceedingly pathogenic to humans is closely related to random genetic recombina-
tion in the host. Although there is a strict genetical relation between SARS-CoV-2 
and SARS-CoV, it is explicit that SARS-CoV-2 has a unique feature providing 
rapidly spread worldwide [157].
SARS-CoV-2 genome sequence is much more resembles a SARS-like bat rather 
than SARS-CoV [158, 159]. Two open reading frames translating the replication- 
and transcription-related gene into two large non-structural polyproteins [156]. 
Ribosomal frameshifting contributes to translate two different but overlapping 
open reading frames. Besides these nonstructural proteins, the subgenomic RNA 
also encodes the viral genome packaging protein N (nucleocapsid), and the viral 
coating proteins M (membrane), E (envelope), and S (spike) as the structural 
proteins. Viral coating proteins, which interact with host surface receptors, is 
generally preferred as the therapeutic target blocking protein–protein interac-
tion [160, 161]. TMPRSS2, the human serine protease, enables S Protein of both 
SARS-CoV and SARS-CoV-2 to prime, and these two viruses use the angiotensin-
converting enzyme 2 (ACE2) receptor in order to bind the host cell as the first 
step of the viral entry mechanism. Unlike SARS-CoV and SARS-CoV-2, the cell 
entry of MERS-CoV depends on the binding of its own spike protein to DPP4 
(dipeptidyl peptidase 4). The RT-PCR analysis of the throat swabs is essential 
to the diagnosis of COVID19 pneumonia, and it takes 3.5 h to provide the 
results [162].
1.7.3 Current treatment approaches
Clinical management puts emphasis on the importance of supportive care and 
prevention of complications due to a lack of specific treatment for COVID-19 pneu-
monia. On the other hand, potential antiviral therapies for the purpose of rapidly 
dealing with this pandemic are taking place on several clinical trials. These trials 
focused on three main targets that include enhancing the host immune system, 
blocking the virus spike protein-host cell surface receptor interaction, and vaccine 
development [163].
Methods in Molecular Medicine
14
1.7.4 Human Papillomavirus genome and treatment
HPV genome, which is a double-stranded circular DNA, has the early (E) genes 
that are responsible for replication and transcription, and the late (L) genes that are 
responsible for viral capsid proteins. In the early stage of HPV infection, the highly 
expressed E1 and E2 proteins provide the maintaining of viral replication and 
transcription within the cervical cell [164].
HPVs, unlike SARS coronaviruses, are non-enveloped viruses and don’t have a 
specific host cell receptor that initiates the viral infection. Additionally, HPVs have 
many different genotypes such as HPV type 16 and type 18 which are known as the 
reason for cervical cancer. HPV infection may cause low-grade cytological changes 
on Papanicolaou smears, or low-grade squamous intraepithelial lesions [165]. When 
malignant conversion considered, viral oncoproteins E6 and E7 attach, respectively, 
tumor suppressor protein p53 and Rb have a crucial role [166]. Until today, many 
vaccine developments studies have been carried out to protect HPV malignant type 
16 and 18. For example, the clinical vaccine Gardasil 9 provides effective protection 
against vaginal, cervical, and vulvar diseases caused by HPV type 16,18 and also its 
5 other different types [167].
2. Conclusion
The chapter outlined the unique mechanism of each disease. Depending of the 
origin of the disease; deficiency, hereditary, infectious and physiological diseases 
may be treated diversely but the perturbation effect can only be eliminated with 
proper intervention. Current amelioration may be improved by biochemical meth-
ods only if the molecular mechanism is clearly understood. Therefore, molecular 
medicine provides unique solutions to diagnose and treat disease by elucidating 
macromolecular interaction and abnormalities in cells and tissues. The chapter 
summarizes current findings and methods to alleviate and cure the diseases.
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